Compare TXRH & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TXRH | RDY |
|---|---|---|
| Founded | 1993 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.9B | 11.6B |
| IPO Year | 2004 | 2001 |
| Metric | TXRH | RDY |
|---|---|---|
| Price | $168.04 | $13.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 1 |
| Target Price | ★ $193.78 | $16.90 |
| AVG Volume (30 Days) | 1.0M | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.70% | 0.52% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.87 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.46 | $7.72 |
| Revenue Next Year | $9.28 | $3.50 |
| P/E Ratio | $89.64 | ★ $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $153.83 | $12.19 |
| 52 Week High | $197.00 | $15.89 |
| Indicator | TXRH | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 47.19 | 50.17 |
| Support Level | $165.83 | $12.86 |
| Resistance Level | $177.65 | $13.95 |
| Average True Range (ATR) | 5.70 | 0.19 |
| MACD | -1.56 | -0.00 |
| Stochastic Oscillator | 31.67 | 46.41 |
Texas Roadhouse Inc is a restaurant company operating predominantly in the casual dining segment. The company manages its restaurant and franchising operations by concept and, as a result, has identified Texas Roadhouse, Bubba's 33, Jaggers, and retail initiatives as separate operating segments. In addition, it has identified Texas Roadhouse and Bubba's 33 as reportable segments. Maximum revenue for the company is generated from the Texas Roadhouse segment, which is a moderately priced, full-service, casual dining restaurant concept offering steaks, a selection of ribs, seafood, chicken, pork chops, pulled pork, vegetable plates, and an assortment of hamburgers, salads, and sandwiches. Geographically, the majority of the firm's restaurants are in the USA, with a few in foreign countries.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.